Severe falciparum malaria with 7% parasitaemia and one course of IV artesunate
A 26-year-old man working in a forested area of Mondulkiri province presents with 4 days of fever, rigors, headache and vomiting. Temperature 39.6°C, pulse 112/min, blood pressure 100/60 mmHg, respiratory rate 26/min. He is jaundiced and confused; urine output is low. Laboratory: haemoglobin 82 g/L, platelets 42 ×10^9/L, creatinine 186 µmol/L, total bilirubin 68 µmol/L, glucose 4.0 mmol/L. A thick blood film shows Plasmodium falciparum trophozoites with a parasitaemia of 7% of red cells. The hospital has oral artemether–lumefantrine and intravenous artesunate, but the pharmacy has only one adult course of IV artesunate and no intensive care bed. The clinician asks whether oral treatment can be used and whether the patient can be transferred. What is your assessment and advice?
1. Classify the severity of malaria and justify your answer using the findings.
Read the worked answer
Classification. This is severe falciparum malaria. The parasitaemia is 7%, above the 5% threshold used to define severe disease in low-transmission settings. He also has impaired consciousness, jaundice and low urine output with creatinine 186 µmol/L. One severe feature is enough; he has several. Oral artemether–lumefantrine is not appropriate because absorption may be poor and the patient is vomiting and confused.
Advice. Give intravenous artesunate as first-line treatment without delay. The first dose should not be postponed for transfer. Arrange transfer to a facility with monitoring and dialysis capability after the first dose. If IV artesunate were truly unavailable, intramuscular artemether is an alternative, but here it is available. Document the reasoning and the severity criteria in the notes.
2. What immediate laboratory monitoring and supportive management should be arranged, and what infection-control or entomological advice is relevant?
Read the worked answer
Monitoring. Check glucose, potassium, sodium, creatinine, bicarbonate, lactate, haemoglobin and parasitaemia at least every 6–12 hours initially. Watch for hypoglycaemia, fluid overload, acute kidney injury and severe anaemia. Give careful fluid balance and avoid aggressive fluid boluses. Transfuse if Hb falls below 7 g/L with clinical instability, and involve a senior clinician.
Infection control and entomology. Malaria is not spread person to person, so no isolation is needed. Advise bed nets and mosquito avoidance to prevent further transmission. The entomological point is that the local Anopheles vector bites mainly at night; the patient's work in a forested area is the exposure. Notify the malaria programme so that local surveillance and vector control can be strengthened. Screen for other causes of fever if the response is atypical.
3. The single IV artesunate course is available but the patient may need transfer. How should the team prioritize and document the use of the limited drug, and what follow-up is required after parenteral therapy?
Read the worked answer
Limited drug. Give the first dose of IV artesunate immediately; do not hold it for transfer. The standard regimen is 2.4 mg/kg at 0, 12 and 24 hours, then daily until oral therapy is tolerated. The single adult course should be used for this patient because he meets severe-malaria criteria; document the indication, dose, time and batch. Arrange transfer so that subsequent doses are not missed.
Follow-up. When he can swallow, complete a full course of artemisinin-based combination therapy. Notify the national malaria programme and record the case. Monitor parasitaemia until negative and check haemoglobin after 1–3 weeks because post-artesunate delayed haemolysis can occur. Counsel on prevention and document the transfer and treatment plan.